Objective. Leconotide is an w-conotoxin that blocks neuronal voltage sensitive calcium channels. This study compared the antihyperalgesic potencies of leconotide and ziconotide given intravenously alone and in combinations with a potassium channel modulator flupirtine, given intraperitoneally, in a rat model of diabetic neuropathic pain.
Introduction
In the last 20 years there has been much interest in the development of w-conotoxins for themanagement of human pain states [1] . Two of these, GVIA and MVIIA, are potent and selective blockers of Cav2.2 channels and therefore these compounds have been investigated for therapeutic potential in neuropathic pain states. MVIIA and GVIA administered intrathecally cause antinociception in acute, chronic, and neuropathic pain models [1] . This line of research has led to the introduction into clinical practice of ziconotide as an intrathecally administered analgesic for severe pain [2] [3] [4] . This drug is administered intrathecally in an attempt to target selectively Cav2.2 channels in the spinal cord associated with pain and nociception because some serious side effects have been found to be associated with peripheral autonomic dysfunction after administration of drugs of this type [5] [6] [7] [8] .
From the clinical perspective, the need for intrathecal administration is a severe disadvantage of this drug. The technique is invasive and it requires specialized expensive equipment. It would be cheaper and more practical to give these drugs by an ordinary parenteral route such as intravenous or subcutaneous. CVID has a similar potency as GVIA and MVIIA in displacing 125 I-GVIA from Cav2.2 channels in rat brain, but was tenfold more potent than GVIA in inhibiting the current under voltage clamp through the cloned central Cav2.2 channels expressed in Xenopus oocytes [9] . These observations led to CVID (later called leconotide and AM336 and now CNSB004) to be synthesized, manufactured, and developed as an analgesic. The intrathecal route was chosen initially for administration of this drug, because of the toxicity profile of the other w-conotoxins. Preclinical studies were completed [10, 11] and a Phase I/IIa trial in severe cancer pain performed [12, 13] .
There is, however, evidence published that leconotide is less toxic than the other w-conotoxins with greater selectivity for sensory compared with sympathetic nervous system neurones. Experiments with recombinant Cav2.2 channels in frog oocytes have shown that the presence of b3 subunits in the constructs decreases the sensitivity of the channels to blockade by conotoxins. The conotoxin most affected by this was leconotide, and the change in potency was ¥540, i.e., much higher doses of leconotide are needed to affect calcium channels with b3 subunits; this selectivity was much less with ziconotide [9] . It has been reported that b3 subunits are present in Cav2.2 channels in neurones in the sympathetic nervous system and thus one would expect leconotide to have less effect on sympathetic reflexes such as blood pressure control.
This has been supported by work in rabbits using intravenous administration of leconotide and a tilt table to assess blood pressure effects [14] . Leconotide at the dose of 100 mg/kg bolus injection caused a short-lived fall in blood pressure. The authors concluded "CVID" (leconotide) "appears to be relatively weak at inhibiting the reflex response to tilt consistent with its weaker inhibition of rat mesenteric artery constriction to perivascular nerve stimulation." This work suggests that a non-spinal parenteral route of delivery for leconotide may be possible without severe cardiovascular effects. There is also evidence for these drugs being able to penetrate the CNS when given iv [15, 16] .
The experiments described in this article set out to investigate the antihyperalgesic effect of CNSB004 (leconotide) given intravenously in a rat model of diabetic neuropathic pain. Further the antihyperalgesic effects were assessed when the drug was given alone and in combination with flupirtine, a potassium channel modulator which acts to reduce the excitability of central neurones [17] . Finally, a direct comparison of these effects was made with ziconotide (synthetic copy of MVIIA), also given intravenously.
Methods
All experiments were performed on male Wistar rats, weight 120-200 g. This work was carried out with permission of the Monash Medical Centre Committee "B" on Ethics in Animal Experimentation (Project MMCB 2004/ 22) . In all experiments attention was paid to ethical guidelines for the investigation of experimental pain in conscious animals [18] . The experiments were performed in an observer-blinded fashion with parallel negative placebo (saline vehicle) treatment controls. All drug solutions and vehicle were given either intravenously (iv) in a volume of 100 mL or intraperitoneally (ip) in a volume of 1.0 mL.
Materials
Flupirtine maleate (AWD.PHARMA GMBH & CO. KG, LeipzigerStrasse 7-13 01097 Dresden FED REP, Germany), saline, and sterile water for injection were obtained from the pharmacy at Monash Medical Centre (Clayton, Victoria, Australia). Streptozotocin was obtained from Sapphire Bioscience Pty Ltd (Redfern, Australia). CNSB004 (leconotide, formerly AM336) was obtained by courtesy of CNSBio Pty (Abbotsford, Victoria, Australia) from AMRAD Ltd, later known as Zenyth Therapeutics Ltd (Richmond, Victoria, Australia) as a di-L-tartrate salt. Intravenous catheters were made from lengths of nylon catheter (I.D. 0.28 mm, O.D. 0.61 mm). Male Wistar rats were supplied as specified pathogen free HsdBrlHan : WIST strain by Monash University Animal Services, Clayton.
All rats were housed in high topped cages in groups of four per cage in a temperature controlled room with a 12 h-12 h light-dark cycle. The rats were allowed food and water ad libitum. All rats used in this project were made diabetic and hyperalgesic by treatment with streptozotocin (STZ). The maximum no side effect doses (NSED) for drugs administered alone and in combinations were defined and then ranges of doses up to and including those were tested for antihyperalgesia.
Streptozotocin-Induced Diabetic Neuropathy
The methods used in this model were described previously by Courteix et al. [19, 20] , but were modified for use with a heat nociception test [21] . Male Wistar rats, weight 65-85 g, were treated with streptozotocin (STZ; 160 mg/kg ip total dose) dissolved in 0.9% sodium chloride solution. STZ solution was made freshly for each session of STZ treatment. The 160 mg/kg total dose was given in two 80 mg/kg injections on consecutive days. Diabetes was confirmed 1 week after injection of STZ by measurement of tail vein blood glucose levels with AccuCheck Active test strips and a reflectance colorimeter (AccuCheck Glucometer, Roche). Only animals with final blood glucose levels Ն15 mM (90% STZ-treated rats) were deemed to be diabetic. Rats that did not develop diabetes were killed with an overdose of anesthetic (halothane). The rats were retested for hyperglycemia once per week to confirm continued high blood glucose readings. Hyperalgesia was assessed by measurement of paw flick latency (PFL) using the radiant heat plantar test described previously by Hargreaves et al. [21] .
Tests of antihyperalgesia took place 5 weeks after the first injection of STZ when the rats had grown to wt 120-200 g. Animals that had a PFL equal to or below 7.0 seconds (at least 30% less than the value in normal weight-matched rats) were deemed to have developed hyperalgesia/neuropathic pain and thus used in further experiments to assess drug effects; this was >50% of STZ-treated rats. Up to five experiments involving drug or placebo injection were performed on each diabetic hyperalgesic rat, one per day on successive days.
Intravenous Cannulation
Following the 5-week period of diabetes induction all rats were anesthetized using inhalation of halothane (0-5%) and oxygen. Following loss of consciousness and righting reflex each rat was placed supine on a heated animal operating table. The administration of gaseous anesthetic continued via facemask with suitable scavenging to minimize pollution and staff exposure to the anesthetic agent. The hair from the skin of the neck was removed and a small incision made over the neck to expose the jugular vein under aseptic conditions. Ligatures were placed around the vein and an intravenous catheter (I.D. 0.28 mm, O.D. 0.61 mm) was inserted into the vein centrally for 2 cm. This was secured in the vein and then tunnelled subcutaneously to an exit wound in the dorsum of the neck where the catheter was secured with sutures. Wounds were infiltrated with local anesthetic and sutured prior to recovery from anesthesia. The rats were allowed 24-hour recovery prior to nociception testing.
Determination of Maximum No Side Effect Doses
Prior to investigation of the antihyperalgesic effects of leconotide and ziconotide administered intravenously alone and in combinations with intraperitoneal injections of flupirtine, experiments were performed on diabetic rats to define the doses of each drug given alone and in combinations that did not cause any side effect-the maximum NSED. This was achieved in three ways. First all rats were observed for general behavior by an experimenter unaware of the nature of the drug treatment. Second, signs of sedation or CNS depression were assessed by measurement of the movements of rats allowed to move freely in an open field activity monitor. Each rat was subjected to this test on only one occasion to avoid habituation to the test. Third, groups of rats treated with each drug and drug combination had blood pressure and heart rate measurements to find out whether any of the doses or dose combinations caused adverse cardiovascular effects.
General Observations
General behavioral observations were made. In particular the rats were observed for startle responses, lethargy, head shakes and writhing or serpentine movements.
Open Field Activity
The open field activity monitor (MedAssociates Inc. St. Albans, VT) is an enclosure with a quiet and darkened environment. It contains 16 intersecting beams of infrared light. Interruptions of beams by individual rats moving around the enclosure were recorded by computer. These measurements were converted to the total rest time in seconds during a 20-minute period in the apparatus. Animals naïve to drug treatment were acclimatized to the lab environment and individual diabetic rats were selected randomly from a group one at a time. They were injected (ip or iv; see below) with saline, a test drug dose, or a combination of drugs in an operatorblinded fashion. Ten minutes after the drug injection each rat was placed in the open field activity monitor for a 20-minute period. This timing was chosen because preliminary experiments revealed that exploratory activity in the apparatus occurs for 20 minutes only. After 20 minutes in the activity box the amount of exploratory activity by nonsedated rats falls to low levels. Thus the rats were placed in the activity box 10 minutes after drug dosing to allow for drug absorption and stabilization. Rest times were combined for each group of rats that were drug-treated to calculate means Ϯ SEM. These were compared with saline-treated controls using ANOVA with Dunnett post hoc test. The numbers of rats allocated to the groups above were N = 30 for saline treatment and N = 9 for each drug treatment. The numbers included in the analysis shown above differ from those originally tested because some rats did not pass the inclusion criterion of Ն30% hyperalgesia.
Cardiovascular Measurements
Systolic and diastolic blood pressure and heart rate were measured using a noninvasive tail cuff blood pressure recorder with piezo-ceramic pulse detection (BP Recorders series 58000; UgoBasile, Comerio VA, Italy). These parameters were measured every 5 minutes for 10 minutes before and 60 minutes after the following drug treatments:
• Values for each parameter and testing time were combined for each treatment and expressed as means (sem). Statistical comparisons with saline controls were made using repeated measures ANOVA with Dunnett correction.
Nociception Testing
After the development of hyperalgesia in diabetic animals was confirmed by the radiant heat plantar test, more detailed nociception testing paradigms were carried out in diabetic neuropathic animals and weight-matched controls (wt 120-200 g); the control rats were 1-2 weeks younger. The weight-matched control animals were chosen for comparison of paw withdrawal thresholds in diabetic animals to allow for the change in paw plantar fat that can alter the tissue heat conduction and therefore the observed paw withdrawal latency. PFL was measured by the method described by Hargreaves using the Ugo-Basile Plantar Test Apparatus (IR 50; UgoBasile, Comerio VA, Italy) that allowed assessment of hyperalgesia in freely moving rats. It might be argued that a mechanical hyperalgesia test might have been a better choice to yield results more applicable to human experiences of hyperalgesia in diabetic neuropathy. The heat paw withdrawal test for hyperalgesia was used because the alternative mechanical paw withdrawal method (Randall Sellito [22] ) requires manual handling and restraint of the rats and thus increased interindividual variability. The other alternative test for mechanical hyperalgesia, the use of high force Von Frey hairs, was not used because of the difficulty of distinguishing responses of allodynia and hyperalgesia.
An intense thermal stimulus was applied to the right hind paw until paw withdrawal was elicited or a maximum cutoff time of 23 seconds was reached. Paw withdrawal thresholds were measured as shown in Figure 1 in groups of rats 20 minutes and 10 minutes before, immediately before (time 0) and also at 10-minute intervals for a further 60 minutes after the following treatments: The numbers of rats allocated to the groups above were N = 30 for saline treatment and N = 10 for each drug treatment. The numbers included in the analysis shown above differ from those originally tested because some rats did not pass the inclusion criterion of Ն30% hyperalgesia on the day of testing.
Each rat had PFL measurement performed every 10 minutes as shown in Figure 1 . Except for the weightmatched controls, each rat received two injections at points shown by the arrows in Figure 1 : a 0.1 mL iv injection given by a 5-minute infusion while the rat was confined closely in a conical restrainer; and also a 1.0 mL ip injection. Saline controls received saline by both routes and rats treated with ip flupirtine alone had iv saline as well. Rats that received iv conopeptide injections as the sole drug also had ip saline. All of these treatments were given in an observer-blinded fashion.
Time response curves were plotted for the weightmatched rats, saline controls, and for the rats which received injections of the highest NSED or dose combinations of drugs. 
Results

Determination of Maximum No Side Effect Doses
General Observations
There were no abnormal behaviors noted in any rats in this series. In particular, with all the doses and dose combinations used here, including those subsequently shown to cause sedation in the open field activity monitor, no animal was noted by the experimenter to be obviously sedated or to exhibit any abnormal movements.
Open Field Activity
The results from the open field activity monitor experiments are shown in Table 1 . The highest doses of drugs given individually were compared with saline controls statistically. Doses of flupirtine up to 10 mg/kg, leconotide 2 mg/kg, and ziconotide 0.02 mg/kg were non-sedating; these doses caused no increase in resting times compared with saline controls (one-way ANOVA Tukey Kramer post hoc test). However, the higher dose of ziconotide (0.2 mg/kg) caused significant sedation whereas the same dose of leconotide did not. The highest dose combinations of flupirtine with conopeptides that caused no significant sedation were flupirtine at both 2.5 and 5 mg/kg with leconotide 0.02 and also either dose of flupirtine with ziconotide 0.02 mg/kg. Table 2 shows the results of the measurements of blood pressure and heart rate in groups of five rats that were treated with iv and ip injections of the highest non-sedating doses as defined by the results from open field activity monitoring and also ziconotide at the two higher doses of 0.2 and 2 mg/kg iv. None of the non-sedating treatments caused a significant change in systolic or diastolic pressures or heart rate. However, doses of ziconotide greater than 0.02 mg/kg did cause systolic and diastolic hypotension (P < 0.01 repeated measures ANOVA with Dunnett post hoc test comparison with saline-treated rats) whereas doses of leconotide up to and including 2 mg/kg did not.
Cardiovascular Measurements
Therefore we conclude that the maximum NSEDs in rats with diabetic neuropathy that should be the upper limit of doses for testing for antihyperalgesic effects are:
• flupirtine alone 10 mg/kg ip • leconotide alone 2 mg/kg iv • ziconotide alone 0.02 mg/kg iv However, as the upper NSED for flupirtine-leconotide combinations was flupirtine 5 mg/kg with leconotide or ziconotide both at 0.02 mg/kg, (see below) it was decided to limit the maximum dose of flupirtine to be tested alone These graphs also illustrate the timing of nociception testing every 10 minutes with paw withdrawal from noxious heat, and also the drug and saline injections given at the arrows between time points 0 and 10 minutes. The weight-matched controls were handled and restrained in exactly the same manner as the drug and saline-treated rats but they did not receive any injections. All other rats received a slow (5 minutes) intravenous infusion of either saline or conopeptide given at the open arrow. This was performed under close restraint in a conical rat restrainer. The rats were then released and given an intraperitoneal injection of flupirtine or saline given at the solid arrow. All of this was done in an observer-blinded fashion. Thereafter the rats were replaced in the paw withdrawal apparatus in which paw withdrawal from noxious heat was measured every 10 minutes. Values shown here are means (Ϯsem). It can be seen that all rats in drug and saline groups had stable baseline readings at -20, -10, and 0 minutes prior to drug or saline injections and that these values were very similar between treatment groups and very much lower than weight-matched controls; the STZ-induced diabetes had caused hyperalgesia to paw pressure stimulation. Furthermore it can be seen that the injection protocol in the saline-treated controls and even the handling and restraint procedures in the weight-matched controls caused increases in paw withdrawal thresholds at time markers 10, 20, and 30 minutes. However these effects had subsided and the responses to drugs were evident and at a plateau at the 40-, 50-, and 60-minute time markers. Flupirtine caused no significant antihyperalgesic effect. Ziconotide also caused no significant antihyperalgesic effect, either alone or in combination with flupirtine. However, leconotide did cause an antihyperalgesic effect, which was increased by administration in combination with flupirtine.
᭣ to 5 mg/kg to allow a valid comparison with that dose given in combination with the conopeptides. The maximum NSEDs for combinations were:
• flupirtine 5 mg/kg ip in combination with leconotide 0.02 mg/kg iv • flupirtine 5 mg/kg ip in combination with ziconotide 0.02 mg/kg iv
Nociception Testing
The mean paw withdrawal latency for weight-matched normal rats was 11.88 seconds. The mean paw withdrawal latency in the diabetic rats in this study was 7.17 seconds indicating that STZ-induced diabetes had caused hyperalgesia. It can be seen in Figure 1 that all rats in drug and saline groups had stable baseline readings at -20, -10, and 0 minutes prior to drug or saline injections and that these values were very similar between treatment groups and very much lower than weight-matched controls revealing the extent of the hyperalgesia to paw pressure stimulation. Furthermore it can be seen that the injection protocol in the saline-treated controls and even the handling and restraint procedures used in the weightmatched controls caused increases in paw withdrawal thresholds at time markers 10, 20, and 30 minutes. However this effect had subsided and the responses to drugs were evident and at a plateau at the 40-, 50-, and 60-minute time markers; the times used in Equation 1 for calculation of percentage reversal of hyperalgesia. The highest NSED of flupirtine (5 mg) caused no significant antihyperalgesic effect. The highest NSED of ziconotide (0.02 mg) also caused no significant hyperalgesic effect, either alone or in combination with flupirtine. However leconotide did cause an antihyperalgesic effect which was increased by administration in combination with flupirtine.
Dose-response relationships for flupirtine alone (2.5 and 5.0 mg/kg ip), leconotide alone (0.00002-2 mg/kg iv), ziconotide alone (0.002 and 0.02 mg/kg iv), and both conopeptides given in combinations with flupirtine are shown in Figure 2 . The maximum NSED of leconotide (2 mg/kg) caused 51.7% reversal of hyperalgesia compared with 0.4% reversal for the highest non-sedating dose of ziconotide (0.02 mg/kg intravenously; P < 0.001, one-way ANOVA). Leconotide caused dose-related antihyperalgesic effects. Flupirtine caused no significant antihyperalgesic effect at the doses used in this study (2.5 and 5.0 mg/kg). However coadministration of leconotide with those doses of flupirtine led to a much greater antihyperalgesic effect than was caused by the same dose of leconotide given alone. Leconotide (0.02 mg/kg) and flupirtine (5 mg/kg) caused 25.3 Ϯ 7.6 and -6 Ϯ 9.5% reversal of hyperalgesia, respectively when given alone but in combination they caused 84.1 Ϯ 7.2% reversal of hyperalgesia (P < 0.01; one-way ANOVA). The peak value of 84.1% reversal clearly exceeds the maximum antihyperalgesia achievable with either drug given alone at maximum NSED.
By contrast, ziconotide caused no significant antihyperalgesic effect when given alone even at the highest NSED of 0.02 mg/kg. When that dose of ziconotide was given in combination with flupirtine 2.5 and 5 mg/kg, the 26.3% and 17% reversal of hyperalgesia, respectively was not statistically significantly different from saline controls.
Discussion
w-conotoxins (GVIA and MVIIA) are small polypeptides found in marine cone snails. They consist of approximately 25 amino acid residues cross-linked by three disulfide bonds. They were found to be potent and selective blockers of neuronal high voltage gated calcium channels Table 2b Diastolic BP mm Hg Table 2c Heart Rate bpm Leconotide 2 mg/kg did not cause any change in blood pressure. Ziconotide 2 mg/kg caused a mean of 17 mm Hg systolic (2a) and 10 mm Hg diastolic (2b) hypotension. Ziconotide 0.2 mg/kg also caused statistically significant systolic but not diastolic hypotension whereas ziconotide 0.02 mg/kg did cause a small fall in diastolic pressure with no change in systolic values. The conopeptide-flupirtine combinations did not cause any significant change in blood pressure. None of the drugs administered alone or the drug combinations caused significant changes in heart rate (2c).
(Cav2.2), a discovery that has led to these compounds being investigated for the treatment of neuropathic pain and neurodegeneration. One of these compounds, ziconotide (a synthetic copy of MVIIA) is used clinically as an intrathecally administered analgesic for severe pain [2] [3] [4] . This drug is administered intrathecally in an attempt to target selectively Cav2.2 channels in the spinal cord associated with pain and nociception and to avoid side effects caused by actions of the drug at other Cav2.2 channels such as those in the peripheral autonomic nervous system [6] [7] [8] 23] . From the clinical perspective, the need for intrathecal administration limits the applicability to a small number of conditions and patients. It would be cheaper and more practical to give these drugs by an ordinary less invasive parenteral route such as intravenous or subcutaneous, but the side effects in the peripheral sympathetic nervous system seem to make these non-viable options.
A third novel w-conotoxin, CVID, was isolated from the marine cone snail, Conus catus. This peptide of 27 amino acids has three disulphide bridges as with GVIA and MVIIA. However, loop 4 of CVID possesses a sequence divergence that stabilizes the conformation [24] . CVID has a similar potency to GVIA and MVIIA in displacing 125 I-GVIA from Cav2.2 channels in rat brain, but it was shown to be tenfold more potent than GVIA in inhibiting the current under voltage clamp through cloned Cav2.2 channels expressed in Xenopus oocytes [9] . These observations led to CVID (later called leconotide and AM336 and now CNSB004) to be developed as an analgesic. The intrathecal route was originally chosen for administration of this drug, presumably because of the toxicity profile of the other w-conotoxins. Intrathecal leconotide was shown to cause dose-related antinociceptive effects [10, 11] . Furthermore intrathecal bolus doses of CVID (leconotide) had a superior therapeutic index compared with MVIIA (ziconotide). Preclinical studies were completed and a Phase I/IIa trial in severe cancer pain performed [12, 13] . That study concluded that intrathecally administered leconotide (AM336) was safe and well tolerated at dose levels that showed analgesic effects (3-6 mg/h). However, side effects were frequent at the higher doses. They were mainly classified as "nervous system disorders" (nausea, disorientation, dizziness, hallucinations) which resolved upon dose reduction. This seemed to indicate that leconotide suffers the same side effect profile as the other conotoxins and that the potency ratio could not be translated to human practice.
There is, however, evidence that leconotide is less toxic than the other w-conotoxins [11] with greater selectivity for Cav2.2 over Cav2.1 calcium channels [25] as well as for sensory compared with sympathetic nervous system neurones. Experiments with recombinant Cav2.2 channels in frog oocytes have shown that the presence of b3 subunits in the constructs decreases the sensitivity of the channels to blockade by conotoxins. The conotoxin most affected by this was leconotide (CVID, CNSB004) and the change in potency was 540-fold, i.e., much higher doses of Figure 2 Dose-response curves for flupirtine, leconotide, and ziconotide given alone and in combinations compared with saline controls. Leconotide caused a dose-related antihyperalgesic effect in causing reversal of hyperalgesia caused by STZ-induced diabetes. Flupirtine and ziconotide had no antihyperalgesic effect when given alone or in combinations. Flupirtine coadministration with leconotide increased the overall antihyperalgesia. There was no difference in the flupirtine-leconotide synergy when the flupirtine dose was increased from 2.5 to 5 mg/kg. Points shown are means and bars, sem.
leconotide are needed to affect calcium channels with b3 subunits; this selectivity was much less with ziconotide [9] . It has been reported that b3 subunits are present in Cav2.2 channels in neurones in the sympathetic nervous system and thus one would expect leconotide to have less effect on sympathetic reflexes such as blood pressure control. This notion has been supported by work in rabbits using intravenous administration of leconotide and a tilt table to assess blood pressure effects [14] . Leconotide at the dose of 100 mg/kg bolus iv injection caused a shortlived fall in blood pressure. The authors concluded "CVID" (leconotide) "appears to be relatively weak at inhibiting the reflex response to tilt consistent with its weaker inhibition of rat mesenteric artery constriction to perivascular nerve stimulation." This work suggested to the authors of the study presented in this article that a non-spinal parenteral route of delivery for leconotide may be possible without severe cardiovascular effects. Administration by nonspinal parenteral routes (intravenous or subcutaneous) would allow the drug access to voltage sensitive calcium channels outside the CNS. Given that leconotide is unlikely to affect sympathetic neurones at doses that target sensory neurones, one might expect a greater analgesic effect than with spinal administration because of additional actions on peripheral nociceptor nerve endings [14, 26] .
The experiments described in this article set out to investigate the antihyperalgesic effect of CNSB004 (leconotide) given intravenously in a rat model of diabetic neuropathic pain. CNS adverse effects were tested in rats with diabetes using an open field activity monitor. Adverse cardiovascular effects were investigated by measurement of blood pressure and heart rate. This approach revealed a major difference between the two w-conotoxins. Ziconotide caused cardiovascular side effects whereas the same doses of leconotide (0.2 and 2 mg/kg intravenously) did not. Leconotide could also be given intravenously up to a dose of 2.0 mg/kg iv compared with 0.2 mg/kg iv for ziconotide without causing sedation as defined by open field activity monitoring. When administered alone at non-sedating doses that caused no cardiovascular effects, (maximum NSED) leconotide caused dose-related antihyperalgesia when given intravenously whereas ziconotide did not. These observations support the notion above that leconotide is more selective in its action for sensory neurones.
Furthermore, the experiments reported here show potentiation in causing antihyperalgesia in a neuropathic pain model between a KCNQ2-3 (Kv 7.2/7.3) potassium channel modulator (flupirtine) and leconotide. There is a mechanistic explanation for such an interaction between two drugs targeting different ion channels in neurones involved with nociceptive processing. Ion channels are divided into two main classes according to their mode of activation. They are activated in one of two ways: the binding of ligands; or changes in membrane potential. The voltage-gated calcium channels are divided into two groups depending on the size of membrane current needed to cause their activation. Low-voltage activated or T-type (Cav 3.1-3.3; found in neurones and cardiovascular tissues) are opened by small currents leading to the neurone membrane potential rising from the normal -70 mV to -60 mV. On the other hand, high-voltage activated calcium channels, L-, P-, Q-, R-, and N-types (Cav 1.1-1.4; Cav 2.1; Cav 2.3; and Cav 2.2, respectively) activate after much larger currents which cause the membrane potential to depolarize to -20 mV. The latter Cav 2.2 channels are of interest here as it is these channels to which w-conotoxins bind. Voltage-gated potassium channels are also widespread in the body with many subtypes having been described. Neuronal potassium channels (KCNQ2-5 or Kv7.2-7.5) were first described in 1998 after it was discovered that the channel proteins shared common sequences with potassium channels found in cardiac tissues [27] . Neuronal KCNQ channels have been found to be molecular substrates of M channels, and several molecules have been identified as openers or activators of these channels. The M current was originally identified as a membrane hyperpolarizing current caused by muscarine [28] . It is the only hyperpolarizing current that operates around resting membrane potential and thus has the possibility of drastically altering neuronal excitability [3] . When one considers that Cav 2.2 channels are activated by large membrane depolarizations, one might expect that there would be a positive synergy between a drug that reduced depolarizations by increasing the M current (flupirtine) and a drug that blocked Cav 2.2 channels (leconotide).
These results point the way for development and clinical trials for leconotide in the management of persistent pain states when the drug can be given by normal non-spinal parenteral routes of administration. This opens the way for the use of a conopeptide voltage sensitive calcium channel blocker to larger groups of patients not able to use intrathecal catheters and pumps to deliver ziconotide. 
